BioXcel Therapeutics' BXCL701 Receives FDA Fast Track Designation: A New Hope in the Battle Against Small Cell Neuroendocrine Prostate Cancer.
Therapeutics Company Receives FDA Fast Track Designation For Prostate Cancer Treatment
Therapeutics Company Receives FDA Fast Track…
Therapeutics Company Receives FDA Fast Track Designation For Prostate Cancer Treatment
BioXcel Therapeutics' BXCL701 Receives FDA Fast Track Designation: A New Hope in the Battle Against Small Cell Neuroendocrine Prostate Cancer.